{"entity":{"id":"nct04601285","kind":"trial","name":"A Phase I Study of JS108 in Patients With Advanced Solid Tumors","aka":[],"tldr":"This study tests TROP-2-directed treatment; the registry reports that it is terminated.","summary":"The registry lists NCT04601285 as terminated, last updated 2023-07-06. Enrolment is 25 actual participants. Interventions: JS108 (recombinant humanized anti-Trop2 mAb-Tub196 conjugate for injection). Primary measures include First Cycle Dose Limiting Toxicities (DLTs) In Order to Determine the Maximum Tolerated Dose(MTD); Number of participants with adverse events (AEs). The registry reason for stopping is: Sponsor has adjusted study development plan and terminated this clinical study. No results are posted in the registry; this does not exclude separate publications.","status":"withdrawn","asOf":"2026-10-06","links":[{"label":"ClinicalTrials.gov NCT04601285","url":"https://clinicaltrials.gov/study/NCT04601285"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":["trop2"],"drugs":["js108"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04601285","phase":"1","setting":"A Phase I, Open-label, First-in-human, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of Recombinant Humanized Anti-Trop2 mAb-Tub196 Conjugate in Patients With Advanced Solid Tumors.","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","started":"2020-10-28","startedType":"actual","enrolled":25,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04601285/","neighbours":{"target":[{"id":"trop2","kind":"target","name":"TROP2","route":"/targets/trop2/"}],"drug":[{"id":"js108","kind":"drug","name":"JS108","route":"/drugs/js108/"}]}}